Trade Editas Medicine - EDIT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.31 |
| Open | 1.3 |
| 1-Year Change | -88.15% |
| Day's Range | 1.28 - 1.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 1.30 | 0.01 | 0.78% | 1.29 | 1.35 | 1.26 |
| Dec 19, 2024 | 1.31 | -0.02 | -1.50% | 1.33 | 1.34 | 1.26 |
| Dec 18, 2024 | 1.32 | -0.17 | -11.41% | 1.49 | 1.50 | 1.31 |
| Dec 17, 2024 | 1.50 | 0.05 | 3.45% | 1.45 | 1.52 | 1.42 |
| Dec 16, 2024 | 1.47 | 0.08 | 5.76% | 1.39 | 1.58 | 1.37 |
| Dec 13, 2024 | 1.42 | -0.29 | -16.96% | 1.71 | 1.73 | 1.39 |
| Dec 12, 2024 | 1.87 | -0.04 | -2.09% | 1.91 | 1.96 | 1.84 |
| Dec 11, 2024 | 1.97 | -0.07 | -3.43% | 2.04 | 2.07 | 1.88 |
| Dec 10, 2024 | 2.08 | -0.11 | -5.02% | 2.19 | 2.20 | 2.08 |
| Dec 9, 2024 | 2.20 | 0.06 | 2.80% | 2.14 | 2.34 | 2.14 |
| Dec 6, 2024 | 2.11 | 0.20 | 10.47% | 1.91 | 2.12 | 1.87 |
| Dec 5, 2024 | 1.88 | -0.05 | -2.59% | 1.93 | 1.99 | 1.87 |
| Dec 4, 2024 | 1.96 | 0.02 | 1.03% | 1.94 | 2.02 | 1.93 |
| Dec 3, 2024 | 1.96 | -0.19 | -8.84% | 2.15 | 2.16 | 1.95 |
| Dec 2, 2024 | 2.17 | -0.06 | -2.69% | 2.23 | 2.25 | 2.10 |
| Nov 29, 2024 | 2.22 | 0.08 | 3.74% | 2.14 | 2.26 | 2.14 |
| Nov 27, 2024 | 2.18 | -0.04 | -1.80% | 2.22 | 2.26 | 2.16 |
| Nov 26, 2024 | 2.19 | -0.10 | -4.37% | 2.29 | 2.31 | 2.11 |
| Nov 25, 2024 | 2.36 | 0.01 | 0.43% | 2.35 | 2.51 | 2.32 |
| Nov 22, 2024 | 2.41 | 0.05 | 2.12% | 2.36 | 2.51 | 2.31 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Editas Medicine Company profile
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com